Please login to the form below

Not currently logged in
Email:
Password:

Roy Baynes joins Gilead’s oncology division

Former Amgen man to become senior VP, oncology therapeutics at the US biopharma company

Roy Baynes - GileadDr Roy Baynes has been appointed senior VP, oncology therapeutics at US biopharmaceutical company Gilead.

His appointment comes after a 10-year spell at Amgen, where he served as VP of global development and therapeutic area head of haematology and oncology.

“Roy has an extensive background in clinical practice, academic research and in cancer drug development,” said Dr Norbert Bischofberger, executive VP, R&D and chief scientific officer.

“Under his leadership, we are well positioned to advance our growing number of pipeline programmes targeted at both haematological malignancies and solid tumours.”

Baynes will report to Bischofberger as part of his new role leading Gilead's programme in oncology.

Baynes added: “Cancer research is an incredibly challenging and evolving field, but one with great opportunity and I look forward to working closely with the internal team and external collaborators as we seek to develop novel cancer therapies that address significant unmet medical needs.”

Prior to his role at Amgen, Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit.

He was also a professor of medicine, professor of oncology and director of the bone marrow transplant programme during his time at Wayne State.

20th January 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics